DRMA
Dermata Therapeutics, Inc.
Key Financials
Net Income
$-7558557
↑ 38.5%
Operating Income
$-7773598
↑ 37.9%
Total Assets
$7.9M
↑ 122.5%
Total Liabilities
$1.6M
↓ 16.8%
Shareholders' Equity
$6.2M
↑ 298.7%
Cash & Equivalents
$7.5M
↑ 137.9%
EPS (Diluted)
$-8.16
↓ 1.6%
Operating Cash Flow
$-7757559.00
↑ 30.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/16/2026 | View on SEC |
| S-8 | 6/4/2026 | View on SEC |
| SCHEDULE 13D | 6/1/2026 | View on SEC |
| EFFECT | 5/29/2026 | View on SEC |
| 424B3 | 5/29/2026 | View on SEC |
| 8-K | 5/27/2026 | View on SEC |
| S-3/A | 5/22/2026 | View on SEC |
| SCHEDULE 13G/A | 5/13/2026 | View on SEC |
| 10-Q | 5/13/2026 | View on SEC |
| 8-K | 5/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | DRMA |
| Company Name | Dermata Therapeutics, Inc. |
| CIK | 1853816 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858)-223-0882 |